Earnings Call · Q3 FY2024·2024-11-07

Q3 24EPS +6.67%·Rev n/aQ2 24EPS +2.86%·Rev n/aQ1 24EPS 0.00%·Rev n/aQ4 23EPS -4.65%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations or Corporate Communications

Fred Vogt — Interim Chief Executive Officer and President

Brian Gastman — Commercial or Sales Executive

Igor Bilinsky — Head of Manufacturing or Manufacturing Executive

Jean-Marc Bellemin — Chief Financial Officer

Friedrich Graf — Chief Medical Officer

Finckenstein — Chief Medical Officer

−13.8%1d on move date−14.2% vs SPY3d−21.1%5d−30.0%

Research tier

Behavioral profile computed for 7 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access